2019 Clinic Government IT 
FDA Law Blog
JANUARY 15, 2024
Koblitz — You know a court decision is going to be worth reading when the judges compare FDA’s regulatory governance of flavored e-cigarettes to a Shakespearean gaslighting. FDA published a June 2019 guidance , which stated that manufacturers would not need to perform long-term studies or submit long-term data in PMTAs.
FDA Law Blog
OCTOBER 1, 2024
District Court for the District of Columbia (“DDC”) against FDA alleging that the Agency’s structure of NDA review is unconstitutional (by our count the 31st Vanda litigation against FDA or another government entity in the last five years, including appeals). Or consider Vanda’s lawsuit filed in the U.S. In January 2024, the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
AUGUST 4, 2022
On June 27, 2019, Pfizer sought an OIG advisory opinion to ensure that its proposal would not run afoul of federal law. That court granted summary judgment to the government on the APA claim and rejected Pfizer’s narrower reading of the AKS, which would require an element of “corrupt” intent to impose AKS liability. Pfizer, Inc.
PEMBlog
JUNE 14, 2023
Government. 2019 Jul 22;20(5):690-695. Characteristics, Clinical Care, and Disposition Barriers for Mental Health Patients Boarding in the Emergency Department. It is also the final episode in a 5 episode series focused on agitation in children and adolescents. Pediatrics March 2023; 151 (3): e2022057383. 10.1542/peds.2022-057383
FDA Law Blog
OCTOBER 10, 2022
Javitt — On September 28, 2022, the FDA issued the long anticipated final Clinical Decision Support Software Guidance (CDS Guidance), which replaces the revised draft guidance document from 2019. Interpretation of Statutory Criteria Under the Final Guidance. Medical information about a patient.
FDA Law Blog
AUGUST 29, 2021
The federal government does its own version of rebranding with each change in administration. The memorandum cites the 2019 Supreme Court decision, Kisor v. clinical testing of implanted brain computer interface devices for patients with paralysis or amputation), enforcement (e.g., Wilkie , 139 S.
FDA Law Blog
FEBRUARY 2, 2023
Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. adequate to justify the proposed clinical testing.” 21 U.S.C. § 355(i)(1)(A). 42 U.S.C. §
Expert insights. Personalized for you.
115 
Let's personalize your content